Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:BCRX NASDAQ:INVA NASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$253.86+0.2%$216.06$181.75▼$255.99$447.62B0.328.27 million shs9.76 million shsBCRXBioCryst Pharmaceuticals$9.55-3.9%$8.90$6.00▼$10.94$2.53B0.575.39 million shs6.53 million shsINVAInnoviva$23.14-1.8%$22.71$16.52▼$25.15$1.74B0.35908,881 shs879,064 shsIRWDIronwood Pharmaceuticals$4.30+4.1%$3.83$0.67▼$5.78$673.43M0.252.22 million shs3.50 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+16.11%+15.47%+18.02%+38.28%BCRXBioCryst Pharmaceuticals0.00%+10.57%+11.56%+5.19%+6.20%INVAInnoviva0.00%+4.80%+10.04%+2.88%+18.09%IRWDIronwood Pharmaceuticals0.00%+16.67%+15.69%+27.86%+465.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$253.86+0.2%$216.06$181.75▼$255.99$447.62B0.328.27 million shs9.76 million shsBCRXBioCryst Pharmaceuticals$9.55-3.9%$8.90$6.00▼$10.94$2.53B0.575.39 million shs6.53 million shsINVAInnoviva$23.14-1.8%$22.71$16.52▼$25.15$1.74B0.35908,881 shs879,064 shsIRWDIronwood Pharmaceuticals$4.30+4.1%$3.83$0.67▼$5.78$673.43M0.252.22 million shs3.50 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+16.11%+15.47%+18.02%+38.28%BCRXBioCryst Pharmaceuticals0.00%+10.57%+11.56%+5.19%+6.20%INVAInnoviva0.00%+4.80%+10.04%+2.88%+18.09%IRWDIronwood Pharmaceuticals0.00%+16.67%+15.69%+27.86%+465.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$253.81-0.02% DownsideBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70116.75% UpsideINVAInnoviva 2.57Moderate Buy$36.2056.44% UpsideIRWDIronwood Pharmaceuticals 2.43Hold$6.2344.96% UpsideCurrent Analyst Ratings BreakdownLatest IRWD, ABBV, BCRX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026INVAInnoviva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/23/2026ABBVAbbVie Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/23/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/23/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$265.00 ➝ $273.006/23/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$298.006/22/2026ABBVAbbVie Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$260.006/22/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/8/2026ABBVAbbVie Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/1/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.33$15.17 per share16.73($1.83) per share-138.72BCRXBioCryst Pharmaceuticals$874.84M2.77$1.19 per share8.03($0.57) per share-16.75INVAInnoviva$420.69M4.06$4.94 per share4.68$15.71 per share1.47IRWDIronwood Pharmaceuticals$296.15M2.37$0.27 per share16.05($1.61) per share-2.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03125.0615.730.775.79%-576.45%13.39%7/31/2026 (Estimated)BCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A29.84N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)INVAInnoviva$271.17M$6.013.859.81N/A119.89%33.33%22.67%8/5/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.607.17N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)Latest IRWD, ABBV, BCRX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.71%+6.80%340.89%53 YearsBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALatest IRWD, ABBV, BCRX, and INVA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.733.19%7/15/20267/15/20268/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68BCRXBioCryst PharmaceuticalsN/A1.911.88INVAInnoviva0.1921.1320.07IRWDIronwood PharmaceuticalsN/A1.411.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%BCRXBioCryst Pharmaceuticals85.88%INVAInnoviva99.12%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%BCRXBioCryst Pharmaceuticals3.80%INVAInnoviva2.01%IRWDIronwood Pharmaceuticals9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableINVAInnoviva10073.81 million72.33 millionOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableIRWD, ABBV, BCRX, and INVA HeadlinesRecent News About These CompaniesZacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerJune 26 at 6:01 AM | zacks.com5 Small Drug Stocks to Invest in Amid a Biotech ComebackJune 25, 2026 | zacks.com10 small-cap US healthcare stocks with the strongest momentum gradesJune 24, 2026 | msn.comIronwood Pharma Shareholders Reaffirm Board and Governance StructureJune 18, 2026 | tipranks.comInsider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 21,571 Shares of StockJune 18, 2026 | insidertrades.comIronwood Pharma Strengthens Balance Sheet With Note RepaymentJune 15, 2026 | tipranks.comThese healthcare stocks are combining strong gains with reasonable pricesJune 12, 2026 | seekingalpha.comCan Linzess Continue Driving IRWD's Revenue Growth Through 2026?June 11, 2026 | zacks.comIronwood (IRWD) Q1 2026 Earnings Call TranscriptJune 2, 2026 | aol.comAIs Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?June 2, 2026 | insidermonkey.comIronwood Pharmaceuticals Signals Blockbuster Momentum in 2026June 1, 2026 | tipranks.comIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | businesswire.comIRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation UseMay 28, 2026 | zacks.comIronwood, AbbVie win U.S. label expansion for Linzess in pediatric constipationMay 27, 2026 | seekingalpha.comIronwood Pharmaceuticals: A Contrarian Buy OpportunityMay 21, 2026 | seekingalpha.comIs Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?May 20, 2026 | insidermonkey.comTop 10 small‑cap value picks: lowest forward P/Es and strong profitabilityMay 18, 2026 | msn.comIronwood Pharmaceuticals, Inc: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is DueMay 13, 2026 | seekingalpha.com3 Stocks Trading Near $5 With Massive Earnings Upside...February 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRWD, ABBV, BCRX, and INVA Company DescriptionsAbbVie NYSE:ABBV$253.86 +0.51 (+0.20%) Closing price 03:59 PM EasternExtended Trading$254.95 +1.09 (+0.43%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.BioCryst Pharmaceuticals NASDAQ:BCRX$9.55 -0.39 (-3.92%) Closing price 04:00 PM EasternExtended Trading$9.63 +0.08 (+0.80%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Innoviva NASDAQ:INVA$23.14 -0.43 (-1.82%) Closing price 04:00 PM EasternExtended Trading$23.14 +0.00 (+0.02%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Ironwood Pharmaceuticals NASDAQ:IRWD$4.30 +0.17 (+4.12%) Closing price 04:00 PM EasternExtended Trading$4.31 +0.01 (+0.33%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
